1.60
5.88%
-0.10
eFFECTOR Therapeutics Inc stock is currently priced at $1.60, with a 24-hour trading volume of 203.29K.
It has seen a -5.88% decreased in the last 24 hours and a -28.89% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.69 pivot point. If it approaches the $1.58 support level, significant changes may occur.
Previous Close:
$1.70
Open:
$1.71
24h Volume:
203.29K
Market Cap:
$7.53M
Revenue:
-
Net Income/Loss:
$-35.94M
P/E Ratio:
-1.8605
EPS:
-0.86
Net Cash Flow:
$-30.82M
1W Performance:
-10.11%
1M Performance:
-28.89%
6M Performance:
+201.66%
1Y Performance:
+72.04%
eFFECTOR Therapeutics Inc Stock (EFTR) Company Profile
Name
eFFECTOR Therapeutics Inc
Sector
Industry
Phone
858 925 8215
Address
142 North Cedros Avenue, Suite B, Solana Beach
eFFECTOR Therapeutics Inc Stock (EFTR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-25-22 | Downgrade | Stifel | Buy → Hold |
Nov-09-21 | Upgrade | Stifel | Hold → Buy |
Oct-12-21 | Initiated | Credit Suisse | Outperform |
Oct-04-21 | Initiated | Mizuho | Buy |
Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
Sep-20-21 | Initiated | Stifel | Hold |
Sep-13-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
eFFECTOR Therapeutics Inc Stock (EFTR) Latest News
eFFECTOR Therapeutics (NASDAQ:EFTR) Trading Up 2.4% - Defense World
Defense World
Trading Day Review: eFFECTOR Therapeutics Inc (EFTR) Loses Momentum, Closing at 1.66 – DWinneX - The Dwinnex
The Dwinnex
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 ... - GlobeNewswire
GlobeNewswire
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 ... - Yahoo Finance
Yahoo Finance
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.35% - MSN
MSN
MSN - MSN
MSN
eFFECTOR Therapeutics Inc Stock (EFTR) Financials Data
eFFECTOR Therapeutics Inc (EFTR) Net Income 2024
EFTR net income (TTM) was -$35.94 million for the quarter ending September 30, 2023, a -736.80% decrease year-over-year.
eFFECTOR Therapeutics Inc (EFTR) Cash Flow 2024
EFTR recorded a free cash flow (TTM) of -$30.82 million for the quarter ending September 30, 2023, a -26.61% decrease year-over-year.
eFFECTOR Therapeutics Inc (EFTR) Earnings per Share 2024
EFTR earnings per share (TTM) was -$19.00 for the quarter ending September 30, 2023, a -790.91% decline year-over-year.
eFFECTOR Therapeutics Inc Stock (EFTR) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
WORLAND STEPHEN T | Chief Executive Officer |
Aug 11 '23 |
Option Exercise |
0.52 |
33,799 |
17,575 |
261,225 |
About eFFECTOR Therapeutics Inc
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
Cap:
|
Volume (24h):